| ￥3500 | |
| Z04756-100 | |
|
|
|
|
|
|
|
|
|
| Species | Cynomolgus | ||||
| Protein Construction |
|
||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Immobilized CA9/Carbonic Anhydrase IX, His, Cynomolgus at 1μg/ml (100μl/Well) on the plate can bind AntiCA9 Antibody, hFc Tag. Test result was comparable to standard batch. Measured by its esterase activity. The specific activity is > 55 pmol/min/µg. Test result meets the standard. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 41.03 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 50-60 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background | CA9 is a member of the carbonic anhydrases' family, that is often expressed in cancer cells under hypoxic condition. CA9 expression potentially contributes to the regulation of cancer cell differentiation and mediates tumour-associated genes and signalling pathways, including apoptosis, hypoxia, G2M checkpoint, PI3K/AKR/mTOR signalling and TGF-beta signalling pathways. |
| Synonyms | CA9; CAIX; CA-IX; EC 4.2.1.1; G250; MN; P54/58N; PMW1; RCC |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
